Free Trial

Nanobiotix (NBTX) Competitors

Nanobiotix logo
$19.20 -0.08 (-0.41%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$19.26 +0.07 (+0.34%)
As of 10/24/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NBTX vs. AKRO, CRNX, MENS, NAMS, KYMR, SRRK, VKTX, MIRM, LNTH, and ADMA

Should you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.

Nanobiotix vs. Its Competitors

Nanobiotix (NASDAQ:NBTX) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Nanobiotix's return on equity of 0.00% beat Akero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NanobiotixN/A N/A N/A
Akero Therapeutics N/A -15.84%-14.59%

Nanobiotix has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500.

Nanobiotix presently has a consensus target price of $11.00, suggesting a potential downside of 42.71%. Akero Therapeutics has a consensus target price of $73.38, suggesting a potential upside of 36.46%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akero Therapeutics is more favorable than Nanobiotix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanobiotix
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Akero Therapeutics
1 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.31

In the previous week, Akero Therapeutics had 1 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Akero Therapeutics and 7 mentions for Nanobiotix. Akero Therapeutics' average media sentiment score of 1.11 beat Nanobiotix's score of 0.65 indicating that Akero Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nanobiotix
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Akero Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Nanobiotix has higher revenue and earnings than Akero Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nanobiotix$39.18M23.49-$73.73MN/AN/A
Akero TherapeuticsN/AN/A-$252.06M-$2.00-26.89

Summary

Nanobiotix and Akero Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBTX vs. The Competition

MetricNanobiotixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$920.51M$2.63B$6.22B$10.81B
Dividend YieldN/A57.77%5.72%4.81%
P/E RatioN/A27.9431.5030.91
Price / Sales23.49786.96594.92133.93
Price / CashN/A168.8137.2561.86
Price / Book-12.725.6512.056.61
Net Income-$73.73M$33.06M$3.34B$277.10M
7 Day Performance-25.00%3.16%1.93%2.57%
1 Month Performance30.17%8.14%7.77%3.79%
1 Year Performance325.72%-2.49%56.40%33.01%

Nanobiotix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBTX
Nanobiotix
0.6535 of 5 stars
$19.20
-0.4%
$11.00
-42.7%
+304.2%$920.51M$39.18M0.00100News Coverage
Analyst Upgrade
AKRO
Akero Therapeutics
3.8001 of 5 stars
$53.66
-0.4%
$73.38
+36.7%
+87.0%$4.31BN/A-26.8330Positive News
Analyst Forecast
CRNX
Crinetics Pharmaceuticals
4.1959 of 5 stars
$44.43
-1.1%
$74.45
+67.6%
-30.2%$4.23B$1.04M-10.81210Positive News
Analyst Forecast
MENS
Jyong Biotech
N/A$55.70
+0.8%
N/AN/A$4.20BN/A0.0031Positive News
Analyst Forecast
Gap Up
NAMS
NewAmsterdam Pharma
3.3938 of 5 stars
$37.15
+0.3%
$42.00
+13.1%
+89.4%$4.17B$45.56M-22.934Analyst Forecast
Analyst Revision
High Trading Volume
KYMR
Kymera Therapeutics
1.374 of 5 stars
$59.89
+4.7%
$61.26
+2.3%
+20.2%$4.09B$47.07M-17.26170News Coverage
Upcoming Earnings
Analyst Forecast
SRRK
Scholar Rock
4.4658 of 5 stars
$34.28
-13.1%
$48.60
+41.8%
+2.3%$3.79B$33.19M-11.78140Analyst Forecast
High Trading Volume
VKTX
Viking Therapeutics
4.06 of 5 stars
$33.91
+1.0%
$86.42
+154.8%
-53.0%$3.77BN/A-22.1620Trending News
Earnings Report
Analyst Downgrade
Analyst Revision
Gap Up
MIRM
Mirum Pharmaceuticals
3.7368 of 5 stars
$72.17
-0.7%
$76.50
+6.0%
+77.9%$3.65B$336.89M-59.64140Analyst Forecast
LNTH
Lantheus
4.596 of 5 stars
$54.59
+2.0%
$74.50
+36.5%
-48.9%$3.64B$1.53B14.52700Trending News
Analyst Downgrade
ADMA
ADMA Biologics
3.5796 of 5 stars
$14.55
+0.1%
$27.67
+90.1%
-4.9%$3.47B$426.45M16.92530News Coverage
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:NBTX) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners